



# 9 03C0  
PATENT BOX SEQ

Case Docket No. NIH173.001C1

Date: October 22, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Wang, et al.  
App. No. : 10/099,782  
Filed : March 14, 2002  
For : UTILIZATION OF FPRL1 AS  
A FUNCTIONAL RECEPTOR  
BY SERUM AMYLOID A  
(SAA)  
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked  
attachments are being deposited with the United States  
Postal Service as first class mail in an envelope addressed  
to: United States Patent and Trademark Office, P.O. Box  
2327, Arlington, VA 22202, on

October 22, 2002

(Date)  
*Nancy W. Vensko*

Nancy W. Vensko, Reg. No. 36,298

TRANSMITTAL LETTER

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

ATTENTION: BOX SEQUENCE

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed  
by the Office on July 23, 2002, enclosed are:

(X) An extension of time to respond for one month(s) is hereby requested.

Time Extension Fee:

(X) one month (\$110 large entity)

(X) A copy of the Notice to Comply.

(X) Sequence Listing in computer readable format (diskette).

(X) Paper copy of Sequence Listing in 87 pages.

(X) Sequence Submission Statement.


10/28/2002 SDENB0B1 00000050 10099782 110.00 0P  
01 FC:1251

**PATENT**

Case Docket No. NIH173.001C1  
Date: October 22, 2002

---

- (X) Return prepaid postcard.
- (X) A check in the amount of \$110 to cover the extension fees is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.



---

Nancy W. Vensko  
Registration No. 36,298  
Attorney of Record  
Customer No. 20,995  
(805) 547-5585



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/099,782	03/14/2002	Ji Ming Wang	NIH173.001C1

CONFIRMATION NO. 4832

## FORMALITIES LETTER



\*OC00000008500070\*

20995  
KNOBBE MARTENS OLSON & BEAR LLP  
620 NEWPORT CENTER DRIVE  
SIXTEENTH FLOOR  
NEWPORT BEACH, CA 92660

Date Mailed: 07/23/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



#7

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wang, et al. ) Group Art Unit Unknown  
Appl. No. : 10/099,782 )  
Filed : March 14, 2002 )  
For : UTILIZATION OF FPRL1 AS A )  
FUNCTIONAL RECEPTOR BY )  
SERUM AMYLOID A (SAA) )  
Examiner : Unknown )

SEQUENCE SUBMISSION STATEMENT

United States Patent and Trademark Office  
PO Box 2327  
Arlington, VA 22202

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 23, 2002. I hereby state that the amendment made in accordance with 37 C.F.R. §1.825(a), included in the Substitute Sequence Listing submitted herewith is supported in the application, as filed, at page 20, line 34. I hereby state that the Substitute Sequence Listing does not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the Substitute Sequence Listing.

Respectfully submitted,  
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 10/21/02By: 

Nancy W. Vensko  
Registration No. 36,298  
Attorney of Record  
Customer No. 20,995  
(805) 547-5585

O:\DOCS\MXG\MXG-1688.DOC  
101802